Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Operating Leases (2019 - 2025)

Serina Therapeutics (SER) has disclosed Operating Leases for 5 consecutive years, with $377000.0 as the latest value for Q4 2025.

  • Quarterly Operating Leases rose 40.67% to $377000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $377000.0 through Dec 2025, up 40.67% year-over-year, with the annual reading at $377000.0 for FY2025, 40.67% up from the prior year.
  • Operating Leases hit $377000.0 in Q4 2025 for Serina Therapeutics, up from $148000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $675000.0 in Q4 2023 to a low of $148000.0 in Q3 2025.
  • Historically, Operating Leases has averaged $391777.8 across 3 years, with a median of $377000.0 in 2025.
  • Biggest YoY gain for Operating Leases was 40.67% in 2025; the steepest drop was 70.92% in 2025.
  • Year by year, Operating Leases stood at $675000.0 in 2023, then plummeted by 60.3% to $268000.0 in 2024, then skyrocketed by 40.67% to $377000.0 in 2025.
  • Business Quant data shows Operating Leases for SER at $377000.0 in Q4 2025, $148000.0 in Q3 2025, and $362000.0 in Q2 2025.